A study [20] pointed the association of LILRB1 with MS/IFN-β treatment and the expression of different NKR by NK cells and CD8+ T lymphocytes from MS patients and healthy controls were analyzed by flow cytometry. Here, LILRB1 is linked to myeloid sarcoma.